Petet1
24 Oct 2016
Never ....... Really loosing patience now , starting to think that we will NEVER make any decent profit here , and probably not see the large rise that we once expected !
Profitcruncher
27 Sep 2016
rise News about to break? fingers crossed.
Sambram
15 Aug 2016
Progressing well "In the year to April 2016, revenues were £361,000 and they could treble this year. This provides a small contribution to group overheads, which will increase in order to finance further trials. Research client Cancer Research UK Manchester Institute is using Parsortix in ten clinical trials, with a further four likely to start using the technology. Angle raised £9.6m net at 64.5p a share during May this year and there was pro forma net cash of £13.4m at the end of April 2016. This cash is expected to last until at least April 2018, although this may depend on the pace of commercialisation and the opportunities that arise. Angle has been trading in a relatively narrow range in the past few months but further good news could provide an upwards push to the share price." - Northland Capital update on research tree.
photonic
30 Jul 2016
Re: RNS There are 75 million shares. AGL would not see all that 300M market by any means but we would attract a high PE. FDA authorisation and realising sales into the Ovarian market would see this comfortably plus £1 and the SP should react strongly to increased sales as our margins are very high on both machines and consumables. Plus we also have Breast and Prostate to look forward to both with huge markets.Right now research sales are strengthening, so increased evidence of this over H2 while we look forward to the results of the latest trials should give a significant uplift.Short term I will hope for news of more research centre contracts, clinical trial sales and general research sales.
millwallfan
28 Jul 2016
RNS The latest Rns states the global market for ovarian cancer alone is estimated at £300m. Let's assume once all approvals Angle with the world leading technology can get 10 percent of that then by my calculation with under 60 million shares in issue that application alone is worth 50p per share. Comments please. And if correct where will we be when fully operational approvals on other forms of cancer and with FDA approval. The mind boggles. Only downside I can see is limited cash balance to get us through next 18 months.
millwallfan
15 Jul 2016
Re: Posters And with under 60 million shares available on commercialisation the economic rules ofdemand and supply can only lead to significant upside. For me the critical unknown is the basis of future ongoing income. If the company retains direct control over the sale or lease of the test machines AND then charges a unit price per test then the long term income will be exceptional leading to strong dividend payments for the life of the patent. A strong hold for me until this landscape is clarified.
millwallfan
15 Jul 2016
Re: Posters I agree and have felt for some time. I would really be interested in any knowledge or informed opinion on timeline to first commercial application.
autpaxautbellum
15 Jul 2016
Posters Really solid base both financially and technologically established here: this should translate into a much higher SP.
claude reins
15 Jul 2016
Presentations at major European cancer conference Key thing is that 2 of the 3 were independent presentations, from Manchester and Hapsburg., They really show the flexibility and the power of this non-intrusive product. It could be massive,not just because of its results but because it must be so good for patients for clinicians to use a tool which is not invasive at a time when the psychological implications for patients of a cancer diagnosis are so dramatic. 'ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is pleased to announce that significant profile was achieved for ANGLE's Parsortix system at EACR 2016 (the European Association for Cancer Research Biennial Meeting) held in Manchester 9 to 12 July 2016. Importantly, performance of the system was referenced in two keynote presentations by independent investigators, Caroline Dive of Cancer Research UK Manchester Institute and Klaus Pantel of University Medical Centre Hamburg-Eppendorf (UKE) respectively. There were three separate scientific poster presentations on Parsortix accepted for presentation at the conference as follows: 1) Fraunhofer ITEM (Institute for Toxicology and Experimental Medicine) Regensburg, Germany: Surface marker independent enrichment of circulating or disseminated cancer cells from blood or lymph nodes using a microfluidic device 2) Cancer Research UK Manchester Institute: Combined circulating tumour cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancer 3) ANGLE in-house: A highly sensitive method for circulating tumour cell antigen quantification in liquid biopsy The published poster presentations will be uploaded to [link] once available. The published poster presentations add to the growing published evidence in support of the use of ANGLE's Parsortix system to easily and effectively harvest cancer cells from the blood of patients for analysis.
Simbrad
31 May 2016
Just pulled this from Research Tree... Angle has raised £9.6m (net) via a private placing. This supports Angle’s focus on commercialising Parsortix, with the funds being applied to a range of clinical studies to demonstrate utility of the Parsortix system. Additionally, Angle announced that Cancer Research UK Manchester Institute is adopting Parsortix for routine research use, which will provide recurring sales. FY16 results in July will provide a trading update and more details on the R&D expansion strategy, likely to be scaled up with the benefit of the fund.
Good money after bad
26 May 2016
Share issue So does this share issue effectively devalue the company by 20% ?
Simbrad
26 May 2016
Read Beaufort Securities's note on ANGLE PLC (AGL), out this morning, by visiting Research Tree: "Ground-breaking potential in detection of cancer, which is now funded to comprehensively demonstrate Parsotix's utility! Parsortix offers the same clinically relevant information from a patient's blood test, irrespective of its location in the body, that otherwise can only be obtained from an invasive metastatic biopsy. Though extensive development and clinical trials will be required across a wide range of indications before such tests to achieve standard international acceptance by medical and insurance providers, much earlier and elementary testing for cancer detection looks set to become a reality. Significantly in this respect, ANGLE differentiates itself from other medtech companies claiming similar abilities. In recent months, the medical world has become aware of a number of new, innovative, but early stage, non-invasive tests (be they derived from blood, saliva, sweat, antibodies etc.) that are apparently also capable of elementary and accurate detection of cancer. The fact remains, however, that detection in the form of a simple 'most probably yes' or 'most probably no' is, in fact, of only limited use unless the test is also capable of capturing or harvesting the same cancer cells for laboratory analysis. Without this, doctors will remain unable to ascertain key information, including identifying the cancer itself along with the extent to which it is aggressive or benign and therefore how to treat it. As such, ANGLE is the only such detection technology that is capable of offering such analysis and so, in Beaufort's opinion, is much more likely to become the globally recommended standard for hospitals and associated medical institutes. Yesterday's news drove this point home. Not only was the Group able to secure major new funding from professional investors in order to progress clinical studies, but it also confirmed a UK contract which allows for routine clinical and research use, itself a key part of the Group's strategy for commercialisation. The funds now available are expected to be sufficient to cover the next 2 years of planned clinical studies, which will be bolstered further by rising research sales. Assuming all goes to plan, ongoing studies of ovarian cancer should have sufficiently concluded to permit first commercial sales to EU hospitals during 1H'2017. Beyond this, FDA authorisation for metastatic breast cancer is expected to be secured through substantive studies defined by three major US-based centres. Successful conclusion here, potentially offers scope for initial North American commercial sales for MBC later in 2017. Further indications, including ovarian and prostate will seek a similar route with the FDA..."
claude reins
09 May 2016
Why the sustained fallin SP This company seems to be doing ll the right things, especially given the recent major positive announcement on breast cancer treatments This should be a winner on that basis. Any thoughts?
millwallfan
18 Apr 2016
Re: Some people are in the know ? I am in at 49p average with a small holding. I cannot see any major downside as every development over the past couple of years has been positive. T think USA FDA approval will be the watershed so, IMHO, a medium term hold for both growth and future dividend income.
claude reins
18 Apr 2016
Re: Some people are in the know ? As a first time investor on the back of today's news, I am really both confused and disappointed. First, the news seems to be very good and yet the share price fell through the day. I am now 10% down on the back of good news. The price fluctuated wildly with a trade at the highest point at around 4pm when there had been a progressive fall during the day. I cannot identify where are the buys and where are the sales. Maybe some other bb reader can help?Secondly, I am disappointed because of the very promising news re breast cancer announced today. Looking back through the bb, I now realise this is on the back of good comparative results for prostate cancer. What a terrific advantage to be able to identify key issues with a blood test rather than damaging invasive biopsy, damaging in both physical and psychological sense - plus the speed and cost elements.Am I right to be disappointed or have I just taken a sucker punch? Answers on a post card please.
